Novo Nordisk A/S shares rose as surging sales of the blockbuster weight-loss treatment Wegovy reassured investors after rival ...
BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of ...
Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.
EU antitrust regulators to decide on Novo Holdings' Catalent buy by Dec. 6 Novo announced $16.5 billion acquisition in February Novo Nordisk seeking to boost output of Wegovy weight-loss drug ...
The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...
Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its ...
MT Newswires on MSN6h
Novo Nordisk Earnings Ease Investor Concerns, Put Focus on New Obesity Drug TrialNovo Nordisk's (NVO) third-quarter earnings were solid enough to soothe investor jitters and turn the market's attention toward upcoming trial results for a potentially game-changing new weight-loss ...
Novo Nordisk reported its net profit in Q3 hit 27.3 billion Danish ... by December 6 whether to clear Novo Holdings’ ...
Novo Nordisk's blockbuster Wegovy weight-loss drug ... three manufacturing sites previously owned by Somerset, N.J.-based Catalent to boost its production capability. It said Wednesday that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback